IP Library › Granted Patent US 12,708,677
Granted Patent B2
US 12,708,677 · App. 18/346,503 · Granted Aug 18, 2026

Contrast agents, methods for preparing contrast agents, and methods of imaging

Inventors: Jenny Jie Yang (Marietta, GA); Zhiren Liu (Atlanta, GA); Jie Jiang (Atlanta, GA); Shenghui Xue (Atlanta, GA); Jinjuan Qiao (Atlanta, GA); Mani Salarian (Decatur, GA)
Assignee: Georgia State University Research Foundation, Inc.
A61K49/14A61K49/126A61K49/143
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,708,677
App. No.
18/346,503
Filed
Jul 3, 2023
Granted
Aug 18, 2026
Kind
B2
Art Unit
1678
USPC
435/7.21
Abstract

Embodiments of the present disclosure provide for contrast agents, methods of making contrast agents, and methods of using contrast agents, and the like.

Claims (21)

1 . A contrast agent comprising a modified parvalbumin scaffold polypeptide, wherein one or more amino acids of the scaffold polypeptide form at least one paramagnetic metal ion chelating site, and further comprising a paramagnetic metal ion bound to at least two of the amino acids forming the at least one paramagnetic metal ion chelating site,

wherein the modified parvalbumin scaffold polypeptide has at least one amino acid substitution that modifies at least one of the metal selectivity of the binding site, increases binding affinity for the metal, or increases serum stability of the contrast agent, and wherein the at least one amino acid substitution is selected from the group consisting of S56D, E60D, G99D, and F103W, wherein the amino acid positions are numbered according to SEQ ID NO: 38, and

wherein the paramagnetic metal ion is Mn(II).

2 . The contrast agent of claim 1 , wherein the modified parvalbumin scaffold polypeptide has an amino acid sequence having at least 90% similarity to any of SEQ ID Nos: 28-38.

3 . The contrast agent of claim 1 , wherein the modified parvalbumin scaffold polypeptide has an amino acid sequence selected from the group consisting of SEQ ID Nos: 28-38.

4 . The contrast agent of claim 1 , including at least one post-translational modification.

5 . The contrast agent of claim 1 , further comprising at least one polyethylene glycol (PEG) group or glucan group attached to the modified parvalbumin scaffold polypeptide.

6 . The contrast agent of claim 5 , wherein the PEG has a molecular weight of about 1 to 100 kDa.

7 . The contrast agent of claim 5 , wherein the PEG is attached to the modified parvalbumin scaffold polypeptide via a lysine, a glutamic acid, an aspartic acid, a cysteine, the polypeptide carboxy-terminus, the polypeptide amino-terminus, or a combination thereof.

8 . The contrast agent of claim 1 , wherein at least two metal ion chelating sites are comprised of amino acids of the modified parvalbumin scaffold polypeptide, and wherein each of the metal ion chelating sites has a paramagnetic ion independently bound thereto.

9 . The contrast agent of claim 1 , wherein at least one metal ion chelating site is at least substantially embedded within the modified parvalbumin scaffold polypeptide.

10 . The contrast agent of claim 1 , further comprising a targeting agent attached to the polypeptide.

11 . The contrast agent of claim 10 , wherein the targeting agent targets to Her-2, EGFR, GRPR, integrin, or collagen.

12 . The contrast agent of claim 10 , wherein the targeting agent targets to VEGFR.

13 . A method of imaging a sample comprising:

contacting a sample with a composition comprising the contrast agent of claim 1 ;

introducing the sample contacted with the composition to an imaging system;

detecting a signal generated by or from the contrast agent of the introduced sample; and

generating an image of the sample from the signal.

14 . The method of claim 13 , wherein the modified parvalbumin scaffold polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID Nos: 28-38.

15 . The method of claim 13 , wherein the imaging system is a PET system.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 10, 2023
From: YANG, JENNY JIE; LIU, ZHIREN; JIANG, JIE; XUE, SHENGHUI; QIAO, JINJUAN; SALARIAN, MANI
To: GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC.
Reel/Frame 065165/0893 →
Continuity (5)
Continuation 17068215 · Oct 12, 2020
Continuation 15910893 · Mar 2, 2018
Continuation 12935413 · Apr 2, 2009
Provisional Application 61041693 · Apr 2, 2008
Related Publication 20240082434A1 · Mar 14, 2024
References Cited (87)
US 4508625A · Graham · 1985 [cited by applicant]
US 5679548A · Barbas et al. · 1997 [cited by applicant]
US 5690903A · Hainfeld · 1997 [cited by applicant]
US 5922302A · Goldenberg et al. · 1999 [cited by applicant]
US 6197258B1 · Thompson et al. · 2001 [cited by applicant]
US 7405320B2 · McBride et al. · 2008 [cited by applicant]
US 8173105B2 · Yang et al. · 2012 [cited by applicant]
US 10814020B2 · Yang · 2020 [cited by examiner]
US 10849993B2 · Yang · 2020 [cited by examiner]
US 11419954B2 · Yang · 2022 [cited by examiner]
US 11426471B2 · Yang · 2022 [cited by examiner]
US 11738098B2 · Yang · 2023 [cited by examiner]
US 20020015038A1 · Patel et al. · 2002 [cited by applicant]
US 20020136692A1 · Harron et al. · 2002 [cited by applicant]
US 20030149254A1 · Anderson et al. · 2003 [cited by applicant]
US 20030180222A1 · Zhang et al. · 2003 [cited by applicant]
US 20040208827A1 · McMurry et al. · 2004 [cited by applicant]
US 20060029942A1 · Yang · 2006 [cited by applicant]
US 20060030029A1 · Yang · 2006 [cited by applicant]
US 20060031020A1 · Yang · 2006 [cited by applicant]
US 20090104123A1 · Yang et al. · 2009 [cited by applicant]
EP 1238982 · 2002 [cited by applicant]
WO 2001030398 · 2001 [cited by applicant]
WO 2003014157 · 2003 [cited by applicant]
WO 2003057829 · 2003 [cited by applicant]
WO 2005016387 · 2005 [cited by applicant]
WO 2005097208 · 2005 [cited by applicant]
WO 2006080022 · 2006 [cited by applicant]
WO 2006107794 · 2006 [cited by applicant]
WO 2007009058 · 2007 [cited by applicant]
WO 2007030802 · 2007 [cited by applicant]
Office Action, dated Feb. 8, 2023, received in connection with corresponding EP Patent Application No. 8204561.7. [cited by applicant]
Jiang, Jie, “Tuning Calcium Bindging Affinities with Related Biological Functions of Calmodulin and Designing Protein Based Contrast Agent,” Dissertation, Georgia State University, Department of Chemistry, 2011, 230 pag… [cited by applicant]
Pu, Fan, Development of Novel Protein-Based MRI Contrast Agents for the Molecular Imaging of Cancer Biomarkers, Dissertation, Georgia State University, Department of Chemistry, 2014, 299 pages. [cited by applicant]
Xue, Shenhui, et al., “Protein MRI contrast agent with unprecedented metal selectivity and sensitivity for liver cancer maging,” PNAS, vol. 112, No. 21, 2015, pp. 6607-6612. [cited by applicant]
Henzel, et al. “15N nuclear magnetic resonance relaxation studies on rat-parvalbumin and the pentacarboxylate variants, S55D and G98D.” Protein Science, 2002, vol. 11, pp. 158-173. [cited by applicant]
Henzel, et al. “Estimation of parvalbumin Ca2+- and Mg2+-binding constants by global least-squares analysis of isothermal titration calorimetry data.” Analytical Biochemistry, 2003, vol. 319, pp. 216-233. [cited by applicant]
Lee, et al. “Crystal Structure of a High-Affinity Variant of Rat a-Parvalbumin.” Biochemistry, 2004, vol. 43, pp. 10008-10017. [cited by applicant]
Bertini, et al. “Tuning the Affinity for Lanthanides of Calcium Binding Proteins.” Biochemistry, 2003, vol. 42, pp. 8011-8021. [cited by applicant]
Haiech, et al. “Restoration of the Calcium Binding Activity of Mutant Calmodulins toward Normal by the Presence of a Calmodulin Binding Structure.” J. Biological Chemistry, 1991, vol. 266, No. 6, pp. 3427-3431. [cited by applicant]
Chattopadhyaya, et al. “Calmodulin Structure Refined at 1⋅7 A Resolution.” J. Molecular Biology, 1992, vol. 228, pp. 1177-1192. [cited by applicant]
Caravan et al. Gadolinium-binding helix-turn-helix peptides: DNA-dependent MRI contrast agents. Chem. Commun 2003, pp. 2574-2575. [cited by applicant]
Roberts M Jet al: “Chemistry for peptide and protein PEGylation”, Advanced Drug Delivery Reviews, Elsevier, Amsterdam, NL, val. 54, No. 4, Jun. 17, 2002 (Jun. 17, 2002}, pp. 459-476. [cited by applicant]
Veron Ese F Metal: “PEGylation, successful approach to drug delivery”, Drug Discovery Today, Elsevier, Rahway, NJ, US, va 1.10, No. 21, Nov. 1, 2005 (Nov. 1, 2005), pp. 1451-1458. [cited by applicant]
Bogdanov A A et al: “Long-Cirulcating Blood Pool Imaging Agents”, Advanced Drug Delivery Reviews, Elsevier, Amsterdam, NL, vol. 16, No. 2/03, Jan. 1, 1995 (Jan. 1, 1995), pp. 335-348. [cited by applicant]
Strijkers G J et al: “Relaxivity of liposomal paramagnetic MRI contrast agents”, Magnetic Resonance Materials in Physics, Biology and Medicine, Chapman and Hall, London, GB, val. 18, No. 4, Sep. 1, 2005 (Sep. 1, 2005), … [cited by applicant]
Dan M. J. Doble et al: “Optimization of the Relaxivity of MRI Contrast Agents: Effect of Poly( ethylene glycol) Chains on the Water-Exchange Rates of Gd Ill Complexes”, Journal of the American Chemical Society, va I. 12… [cited by applicant]
Aaron M. Mohs et al: “-cystine): Effect of PEG Chain Length on in Vivo Contrast Enhancement in MRI”, Biomacromolecules, val. 6, No. 4, Jul. 1, 2005 (Jul. 1, 2005 }, pp. 2305-2311. [cited by applicant]
Shi Ke et al: “Imaging taxane-induced tumor apoptosis using PEGylated, 1111 n-labeled annexin V.”, The Journal of Nuclear Medicine, val. 45, No. 1, Jan. 1, 2004 (Jan. 1, 2004), pp. 108-115. [cited by applicant]
Jenny J Yang et al: “Rational design of protein-based MRI contrast agents”, Journal of the American Chemical Society, ACS Publications, US, val. 130, No. 29, Jul. 23, 2008 (Jul. 23, 2008), pp. 9260-9267. [cited by applicant]
Shunyi Li et al: “PEGylation of protein-based MRI contrast agents improves relaxivities and biocompatibilities”, Journal of Inorganic Biochemistry, Elsevier Inc, US, val. 107, No. 1, Nov. 8, 2011 (Nov. 8, 2011}, pp. 111… [cited by applicant]
Jingjuan Qiao et al: “HER2 Targeted Molecular MR Imaging Using a De Novo Designed Protein Contrast Agent”. PLOS ONE, val. 6, No. 3, Mar. 24, 2011 (Mar. 24, 2011), p. e18103. [cited by applicant]
Shenghui Xue et al: “Design of a novel class of protein-based magnetic resonance imaging contrast agents for the molecular imaging of cancer biomarkers”, Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnolo… [cited by applicant]
Lixia Wei et al: “Protein-Based MRI Contrast Agents for Molecular Imaging of Prostate Cancer”, Molecular Imaging and Biology, Springer-Verlag, NE, vol. 13, No. 3, Jun. 24, 2010 (Jun. 24, 2010), pp. 416-423. [cited by applicant]
European Search Report; Sep. 16, 2014 for application EP09755461; 14 pages, Munich. [cited by applicant]
Patonay et al. Near-infrared fluorogenic labels: new approach to an old problem. Analytical chemistry 1991, vol. 63, No. 6, pp. 321-327. [cited by applicant]
Mesecar, et al., “Orbital Steering in the Catalytic Power of Enzymes: Small Structural Changes with Large Catalytic Consequences,” Science Jul. 11, 1997:277(5323):202-6. [cited by applicant]
Smith, et al., “Entry for Quaternary Structure,” Oxford Dictionary of Biochemistry and Molecular Biology, Oxford University Press, NewYair 1997, p. 551. [cited by applicant]
Richmond, et al., “Engineered Metal Binding Sites on Green Fluorescence Protein,” Biochemical and Biophysical Research Communications, vol. 268, No. 2, Feb. 16, 2000, pp. 462-465. [cited by applicant]
Romoser, et al., “Detection in Living Cells of Ca-2+-dependent Changes in the Fluroescence Emission of an Indicator Composed of Two Green Fluorescent Protein Variants Linked by a Calmodulin-binding Sequence: A New Class… [cited by applicant]
Nagai, et al., “Circularly Permuted Green Fluorescent Proteins Engineered to Sense Ca2+” Proceedings of the National Academy of Sciences of USA, National Academy of Science, Washington, DC, vol. 98, No. 6, Mar. 13, 2001… [cited by applicant]
Wilkins, et al., “Metal-Binding Studies for a De Novo Designed Calcium-Binding Protein,” Protein Engineering, val. 15, No. 7, Jul. 2002, pp. 571-574. [cited by applicant]
Hellinga, et al., “Protein Engineering and the Development of Generic Biosensors,” Trends in Biotechnology. val 16, No. 4, 1998, p. 183. [cited by applicant]
Supplemental European Search Report dated Aug. 25, 2009. [cited by applicant]
Elbanowski, et al., “Fluorescence of Lanthanide (Ill) Complexes in Aqueous Solutions: The Influence of pH and Solution Composition,” Monatshfte fur Chemie, 1985, val. 116, pp. 901-911. [cited by applicant]
Johnson, et al., “Structural Changes Required for Activation of Protein Care Induced by CA2+ Binding to a High Affinity Site that Does Not Contain g-Carboxyglutamic Acid,” The Journal of Biological Chemistry, 1983, vol.… [cited by applicant]
Lewis, et al., “Fiuroescence Binding Assay for a Small Peptide Based on a GFP Fusion Protein,” Analytica Chimica Acta., val. 397. 1999, pp. 279-286. [cited by applicant]
Schlyer et al., “Time-Resolved Room Temperature Protein Phosphorescence: Nonexponential Decay from Single Emitting Tryptophans,” Biophysical Journal, val. 67, 1994, pp. 1192-1202. [cited by applicant]
Yang, et al., “The Molecular Structure of Green Fluorescent Protein,” Nature Biotechnology, vol. 14, 1996, pp. 1246-151. [cited by applicant]
Shelling, et al., “Protein Nuclear Magnetic Resonance Studies of the Interaction of the Lanthanide Yetterbium and Lutetium with Apo-and Calcium Saturated Porcine Intestinal Calcium Binding Protein,” Biochemistry, 1985, … [cited by applicant]
Yang, et al., “Rational Design of a Calcium-Binding Protein,” Journal of the American Chemical Society, Apr. 2003, vol. 125, pp. 6165-6171. [cited by applicant]
Ye, et al., “A Grafting Approach to Obtain Site-Specific Metal-Binding Properties of EF-Hand Proteins,” Protein Engineering, vol. 16, No. 6; pp. 429-434, 2003. [cited by applicant]
Ye, et al., “Metal Binding Affinity and Structural Properties of an Isolated EF-Loop in a Scaffold Protein,” Protein Engineering, vol. 14, No. 12, pp. 1001-1 013; 2001. [cited by applicant]
MacKenzie, et al., “Bifunctional Fusion Proteins Consisting of a Single-Chain Antibody and an Engineered Lanthanide=Binding Protein,” Immunotechnology 1 (1995), pp. 139-150. [cited by applicant]
Lee, et al., “Isolated EF-Loop Ill of Calmodulin in a Scaffold Protein Remains Unpaired in Solution Using Pulsed-Field-Gradient NMR Spectroscopy,” Biochimica et Biophysica Acta; 1598 (2002), pp. 80-87. [cited by applicant]
Miyawaki, et al., Fluorescent Indicators for CA2+ Based on Green Fluorescent Proteins and Calmodulin; Nature, vol. 388, Aug. 28, 1997, pp. 882887. [cited by applicant]
Prasher, et al., “Primary Structure of the Aequorea Victoria Green-Fluorescent Protein,” Gene, 1992, vol. 111, 99. 229-233. [cited by applicant]
Yang et al., “Obtaining Site-Specific Calcium-Binding Affinities of Calmodulin,” Protein and Peptide Letters, vol. 10, No. 1 4, pp. 331-345, 2003. [cited by applicant]
Kawasaki, et al., “Classification and Evolution of EF-Hand Proteins,” BioMetals; 1998, vol. 11, pp. 275-295. [cited by applicant]
International Search Report and Written Opinion, dated Jul. 14, 2008. [cited by applicant]
Anton, et al., “Biotinylation of a Bombesin” 1991, Peptides, 12, pp. 375-381. [cited by applicant]
International Search Report and Written Opinion dated Nov. 28, 2007. [cited by applicant]
Cohen, et al., “Ferritin as an Endogenous MRI Reporter for Noninvasive Imaging of Gene Expression in C6 Glioma Tumors,” Neoplasia, Feb. 2005, val. 7, No. 2, pp. 109-111. [cited by applicant]
Pessl, et al., “A Designed Metal-Binding Protein with a Novel Fold,” Nature, Mar. 25, 1993, 362, 367, 369 (online). [cited by applicant]
International Search Report and Written Opinion dated Feb. 1, 2007. [cited by applicant]
International Preliminary Report on Patentability dated Oct. 14, 2010. [cited by applicant]
Evenäs J et al. Ca2+ binding and conformational changes in a calmodulin domain. Biochemistry. Sep. 29, 1998;37 (39):13744-54. [cited by applicant]